Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kathleen McKeever

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Caring : National Association for Home Care Magazine|September 28, 2013
Emergency preparednes: Managing crisis in the community during Hurricane SandyKathleen McKeever, Sherl Brand
Clinical Pharmacology in Drug Development|March 31, 2021
The Pharmacokinetics of Triheptanoin and Its Metabolites in Healthy Subjects and Patients With Long-Chain Fatty Acid Oxidation DisordersSun Ku Lee, Manju Gupta, Jack Shi, et al.
Expert Opinion on Drug Discovery|July 25, 2012
Challenges of general safety evaluations of biologics compared to small molecule pharmaceuticals in animal modelsRakesh Dixit, Laurie A Iciek, Kathleen McKeever, et al.
Arthritis Research & Therapy|April 10, 2013
B-cell targeted therapeutics in clinical developmentStephan Blüml, Kathleen McKeever, Rachel Ettinger, et al.
International Immunopharmacology|August 30, 2003
Differential in vivo effects of rituximab on two B-cell subsets in cynomolgus monkeysYulia Vugmeyster, Kathy Howell, Kathleen McKeever, et al.
Clinical Pharmacology in Drug Development|July 31, 2022
Population Pharmacokinetics of Heptanoate in Healthy Subjects and Patients With Long-Chain Fatty Acid Oxidation Disorders Treated With TriheptanoinSun Ku Lee, Nathalie H Gosselin, Claudia Jomphe, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|October 13, 2010
Developmental immunotoxicology assessment of rituximab in cynomolgus monkeysAnu Vaidyanathan, Kathleen McKeever, Banmeet Anand, et al.
Clinical Pharmacokinetics|December 6, 2018
Correction to: Pharmacokinetic and Pharmacodynamic Modeling to Optimize the Dose of Vestronidase Alfa, an Enzyme Replacement Therapy for Treatment of Patients with Mucopolysaccharidosis Type VII: Results from Three TrialsYulan Qi, Kathleen McKeever, Julie Taylor, et al.
Journal of Clinical Pharmacology|August 5, 2021
Population Pharmacokinetics and Pharmacodynamics of Burosumab in Adult and Pediatric Patients With X-linked HypophosphatemiaSun Ku Lee, Nathalie H Gosselin, Julie Taylor, et al.
Clinical Pharmacokinetics|November 24, 2018
Pharmacokinetic and Pharmacodynamic Modeling to Optimize the Dose of Vestronidase Alfa, an Enzyme Replacement Therapy for Treatment of Patients with Mucopolysaccharidosis Type VII: Results from Three TrialsYulan Qi, Kathleen McKeever, Julie Taylor, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Caring : National Association for Home Care Magazine|September 28, 2013
Emergency preparednes: Managing crisis in the community during Hurricane SandyKathleen McKeever, Sherl Brand
Clinical Pharmacology in Drug Development|March 31, 2021
The Pharmacokinetics of Triheptanoin and Its Metabolites in Healthy Subjects and Patients With Long-Chain Fatty Acid Oxidation DisordersSun Ku Lee, Manju Gupta, Jack Shi, et al.
Expert Opinion on Drug Discovery|July 25, 2012
Challenges of general safety evaluations of biologics compared to small molecule pharmaceuticals in animal modelsRakesh Dixit, Laurie A Iciek, Kathleen McKeever, et al.
Arthritis Research & Therapy|April 10, 2013
B-cell targeted therapeutics in clinical developmentStephan Blüml, Kathleen McKeever, Rachel Ettinger, et al.
International Immunopharmacology|August 30, 2003
Differential in vivo effects of rituximab on two B-cell subsets in cynomolgus monkeysYulia Vugmeyster, Kathy Howell, Kathleen McKeever, et al.
Clinical Pharmacology in Drug Development|July 31, 2022
Population Pharmacokinetics of Heptanoate in Healthy Subjects and Patients With Long-Chain Fatty Acid Oxidation Disorders Treated With TriheptanoinSun Ku Lee, Nathalie H Gosselin, Claudia Jomphe, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|October 13, 2010
Developmental immunotoxicology assessment of rituximab in cynomolgus monkeysAnu Vaidyanathan, Kathleen McKeever, Banmeet Anand, et al.
Clinical Pharmacokinetics|December 6, 2018
Correction to: Pharmacokinetic and Pharmacodynamic Modeling to Optimize the Dose of Vestronidase Alfa, an Enzyme Replacement Therapy for Treatment of Patients with Mucopolysaccharidosis Type VII: Results from Three TrialsYulan Qi, Kathleen McKeever, Julie Taylor, et al.
Journal of Clinical Pharmacology|August 5, 2021
Population Pharmacokinetics and Pharmacodynamics of Burosumab in Adult and Pediatric Patients With X-linked HypophosphatemiaSun Ku Lee, Nathalie H Gosselin, Julie Taylor, et al.
Clinical Pharmacokinetics|November 24, 2018
Pharmacokinetic and Pharmacodynamic Modeling to Optimize the Dose of Vestronidase Alfa, an Enzyme Replacement Therapy for Treatment of Patients with Mucopolysaccharidosis Type VII: Results from Three TrialsYulan Qi, Kathleen McKeever, Julie Taylor, et al.
Pageof 3